<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2026"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ntrb="http://nutriband.com/20260430"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ntrb-20260430.xsd" xlink:type="simple"/>
    <context id="cref_801113801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1130380903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-01</instant>
        </period>
    </context>
    <context id="cref_1660901923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2026-02-13</startDate>
            <endDate>2026-02-13</endDate>
        </period>
    </context>
    <context id="cref_1599877957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_390752152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:SorrentoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="cref_546947719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="cref_1955509422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2023-07-25</startDate>
            <endDate>2023-07-25</endDate>
        </period>
    </context>
    <context id="cref_606350720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="cref_1964202127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2022-02-01</instant>
        </period>
    </context>
    <context id="cref_1355163824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ntrb:KindevaDrugDeliveryLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1912646503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ntrb:MrGoodmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="cref_571041992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_617777440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="cref_1426843771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1272226741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1593737962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:FourPTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1013089313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:FourPTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1244462413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:PoconoPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1031402892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:PoconoPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_403041879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1933620450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1610623169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_445070040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1714920428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_2063022680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_775598171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1247594112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1310356150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:FourPTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_802128550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:FourPTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1568411139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:PoconoPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1873059364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:PoconoPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_17202391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:ResearchAndDevelopment4PTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1796246010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:ResearchAndDevelopment4PTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_91145137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:SellingGeneralAndAdministrativeCorporateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1029258840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:SellingGeneralAndAdministrativeCorporateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1751454475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:SellingGeneralAndAdministrative4PTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_770823313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:SellingGeneralAndAdministrative4PTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_600097741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:SellingGeneralAndAdministrativePoconoPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_442966646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:SellingGeneralAndAdministrativePoconoPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_545487639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1570954804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1574703023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_385634131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1449916209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1775938043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_487926479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_398687509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1680837298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_718138601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1914682739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1050754111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1434214127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_676550284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_2047779281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_820516612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1609161670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_610342924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_266825755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_258092401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1606065240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_2016368059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_164717851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_517838176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_616493571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_2003686783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_478771025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_926476485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_455166402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_601733390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_540884474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_1395898379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_864283349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-31</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="cref_1815088329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_1753317030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_1938127607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_1381066858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_341740768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1186377537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1780810116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_385813736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="cref_1974626520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="cref_10807001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-03</instant>
        </period>
    </context>
    <context id="cref_1328715614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="cref_988379700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="cref_1506999862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="cref_1602551012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="cref_639260467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1162610843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePrices750Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_327320294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePrices750Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1231422266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePrices643Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1933317982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePrices643Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_483198360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePriceSixPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_864234884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePriceSixPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_708812864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePriceFourPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1553198873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePriceFourPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_2002267615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesThreePointSevenThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_392548195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ntrb:ExercisePricesThreePointSevenThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1685331535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1330704236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_794142459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_35834288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-31</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="cref_952288185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_1375090296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1786324445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_603781419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="cref_357220360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ntrb:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1439619776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_180139111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="cref_1503019495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_501121315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="cref_894328472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="cref_671162616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="cref_959351278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-09</startDate>
            <endDate>2025-07-09</endDate>
        </period>
    </context>
    <context id="cref_470460901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-09</startDate>
            <endDate>2025-07-09</endDate>
        </period>
    </context>
    <context id="cref_1659322823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="cref_1625954283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="cref_1068088003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="cref_747260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-15</instant>
        </period>
    </context>
    <context id="cref_138024624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1726790181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_2041513663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1856764558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_122751182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:CustomerBaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1651249766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ntrb:CustomerBaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_215442559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:SecuredBorrowingLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_280601010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:SecuredBorrowingLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_341012551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:SecuredBorrowingLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-19</instant>
        </period>
    </context>
    <context id="cref_1625861207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_882060044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1931587099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1925245410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1302937178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-15</instant>
        </period>
    </context>
    <context id="cref_315045102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="cref_864861034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-17</instant>
        </period>
    </context>
    <context id="cref_979954947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-17</instant>
        </period>
    </context>
    <context id="cref_1688693998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:AutomobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_852992327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:AutomobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1492224421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:AutomobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="cref_1865326699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ntrb:AutomobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="cref_888680957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1972791219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_241892646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1035181820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ntrb:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1170331083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ntrb:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_49913731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_28000889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_928023170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_57195344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1446629769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1349139423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1977080082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="cref_85067590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:FourPTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1438364266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1199660357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1490037352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ntrb:SaleOfGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_722521170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ntrb:SaleOfGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1634907155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_438557598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1805760617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1928265586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ntrb:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_323607820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ntrb:CreditLineNoteFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="cref_1483634024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ntrb:CreditLineNoteFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-17</instant>
        </period>
    </context>
    <context id="cref_1831155051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ntrb:CreditLineNoteFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="cref_1319143949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:PoconoPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="cref_1604186989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2018-08-01</instant>
        </period>
    </context>
    <context id="cref_1480997135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:FourPTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-01</instant>
        </period>
    </context>
    <context id="cref_1597596874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:FourPTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-01</instant>
        </period>
    </context>
    <context id="cref_835892109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ntrb:FourPTherapeuticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-01</endDate>
        </period>
    </context>
    <context id="cref_371919607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_1458803835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_1699890394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_839495585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_18426132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_230100510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_1683264468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1456873658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_268181459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_16094978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_21334872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_664487435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_1620482763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_1302239174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_330268729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_1208939897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_847473816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1303687185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_960217129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1365327810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_711521113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1713273969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_311767850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1926437787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1880985516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_368771960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_748811741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_351299798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_962746945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1733830422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
        </entity>
        <period>
            <instant>2026-06-11</instant>
        </period>
    </context>
    <context id="cref_1473919857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ntrb:Warrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1435951752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1592452550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="cref_896398403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_228912319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_425087357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:GoodwillAndIntangiblesImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1682608058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ntrb:GoodwillAndIntangiblesImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_280772982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1511338803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_496935024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1427463371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1336222078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_570831292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:ReportableSubsegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="cref_1998475536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1544052377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1587308201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_137935760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_797744269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_935359791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1748428375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1384332075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_1660144407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_457140472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676047</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <unit id="uref_1130380903">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_1964202127">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="uref_490212018">
        <measure>pure</measure>
    </unit>
    <unit id="uref_1838883110">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_1142227404">
        <measure>shares</measure>
    </unit>
    <unit id="uref_11325532">
        <measure>ntrb:Segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1599877957"
      id="fc_1246197189"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1726790181"
      id="fc_1885911023"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1815088329"
      id="fc_140760890"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1395898379"
      id="fc_1083646122"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_351299798"
      id="fc_1971917034"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_1592452550"
      id="fc_1592452550"
      unitRef="uref_1142227404"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_896398403"
      id="fc_896398403"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_228912319"
      id="fc_228912319"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1683264468"
      id="fc_1862892783"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants
      contextRef="cref_1683264468"
      id="fc_1189226460"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_2047779281"
      id="fc_1710946861"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_1434214127"
      id="fc_193294681"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_1914682739"
      id="fc_1209449450"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_1680837298"
      id="fc_478459098"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_487926479"
      id="fc_1651616215"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_1449916209"
      id="fc_15631382"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_1574703023"
      id="fc_2015684357"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="cref_801113801"
      decimals="0"
      id="fc_11325532"
      unitRef="uref_11325532">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="cref_801113801" id="fc_216246343">http://fasb.org/srt/2026#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:Revenues
      contextRef="cref_802128550"
      id="fc_4609531"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_1310356150"
      id="fc_621715936"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="cref_802128550"
      id="fc_571471521"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="cref_1310356150"
      id="fc_73424698"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="cref_425087357"
      id="fc_425087357"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="cref_1682608058"
      id="fc_1682608058"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_280772982"
      id="fc_280772982"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1511338803"
      id="fc_1511338803"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_496935024"
      id="fc_496935024"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_1427463371"
      id="fc_1427463371"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1336222078"
      id="fc_1336222078"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_570831292"
      id="fc_570831292"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="cref_708812864"
      id="fc_677907702"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="cref_483198360"
      id="fc_1238136706"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="cref_1231422266"
      id="fc_432079429"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="cref_1162610843"
      id="fc_1780239855"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1998475536"
      id="fc_1998475536"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1544052377"
      id="fc_1544052377"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1587308201"
      id="fc_1587308201"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_137935760"
      id="fc_137935760"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="cref_801113801"
      id="fc_1489173357"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_801113801"
      id="fc_919485931"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1439619776"
      id="fc_416180199"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="cref_801113801"
      id="fc_1456788470"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="cref_1439619776"
      id="fc_1922643869"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1592452550"
      id="fc_1688849009"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_797744269"
      id="fc_797744269"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_935359791"
      id="fc_935359791"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_1748428375"
      id="fc_1748428375"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_1713273969"
      id="fc_1681732889"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_1384332075"
      id="fc_1384332075"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_797744269"
      id="fc_1162623625"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_935359791"
      id="fc_59140489"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_311767850"
      id="fc_736267509"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1748428375"
      id="fc_1625273989"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1384332075"
      id="fc_1280401532"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1365327810"
      id="fc_669564191"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="cref_801113801"
      id="fc_1021924811"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="cref_1439619776"
      id="fc_1779153005"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="cref_1439619776"
      id="fc_1338633078"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="cref_801113801"
      id="fc_2123659656"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1439619776"
      id="fc_226473022"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="cref_1660144407"
      id="fc_1660144407"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueGranted
      contextRef="cref_1330704236"
      id="fc_32178986"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="cref_1330704236"
      id="fc_1572536866"
      unitRef="uref_1142227404"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice
      contextRef="cref_1330704236"
      id="fc_1596153309"
      unitRef="uref_1838883110"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExpiredCancelled
      contextRef="cref_1330704236"
      id="fc_848963775"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExercised
      contextRef="cref_1330704236"
      id="fc_322993075"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueGranted
      contextRef="cref_1685331535"
      id="fc_1256447394"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="cref_1685331535"
      id="fc_1996307492"
      unitRef="uref_1142227404"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice
      contextRef="cref_1685331535"
      id="fc_1185320018"
      unitRef="uref_1838883110"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExpiredCancelled
      contextRef="cref_1685331535"
      id="fc_1357309342"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="cref_1685331535"
      id="fc_1249219985"
      unitRef="uref_1142227404"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="cref_1685331535"
      id="fc_1768809550"
      unitRef="uref_1838883110"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExercised
      contextRef="cref_1685331535"
      id="fc_420593725"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue
      contextRef="cref_540884474"
      id="fc_1297631516"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="cref_540884474"
      id="fc_1124983472"
      unitRef="uref_1838883110"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_801113801"
      id="fc_1650888750"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_801113801"
      id="fc_1399571091"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="cref_801113801"
      id="fc_557853092"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="cref_1439619776"
      id="fc_994486119"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="cref_801113801"
      id="fc_249256310"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_801113801"
      id="fc_1297209908"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1439619776"
      id="fc_825301396"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:PurchaseOfTreasuryStock
      contextRef="cref_1439619776"
      id="fc_2044978700"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="cref_801113801"
      id="fc_1247197107"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="cref_1439619776"
      id="fc_600345282"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="cref_801113801"
      id="fc_465813374"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:MeasurementOfOperatingLeaseRightofUseAssetsAndLiabilities
      contextRef="cref_801113801"
      id="fc_1938517055"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="cref_801113801"
      id="fc_530923879"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_601733390"
      id="fc_1854691229"
      unitRef="uref_1838883110"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_601733390"
      id="fc_1243908151"
      unitRef="uref_1142227404"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="cref_601733390"
      id="fc_1995491074"
      unitRef="uref_1838883110"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_16094978"
      id="fc_359753864"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_18426132"
      id="fc_1964624117"
      unitRef="uref_1142227404"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_457140472"
      id="fc_457140472"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants
      contextRef="cref_1439619776"
      id="fc_1939867809"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants
      contextRef="cref_896398403"
      id="fc_1111198461"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants
      contextRef="cref_228912319"
      id="fc_1190521316"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants
      contextRef="cref_16094978"
      id="fc_695372976"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_268181459"
      id="fc_1241231154"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_896398403"
      id="fc_749716040"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1456873658"
      id="fc_9010900"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_228912319"
      id="fc_897113705"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_601733390"
      id="fc_911683903"
      unitRef="uref_1142227404"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsntrinsicValueOutstandingBalance
      contextRef="cref_952288185"
      id="fc_869578959"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsntrinsicValueOutstandingBalance
      contextRef="cref_794142459"
      id="fc_1299203692"
      unitRef="uref_1130380903"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_801113801" id="ixv-5686">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="cref_801113801" id="ixv-5687">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="cref_801113801" id="ixv-5688">0001676047</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="cref_801113801" id="ixv-5689">--01-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_801113801" id="ixv-5690">2027</dei:DocumentFiscalYearFocus>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_801113801" id="ixv-5691">NV</dei:EntityIncorporationStateCountryCode>
    <dei:DocumentType contextRef="cref_801113801" id="ixv-7420">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="cref_801113801" id="ixv-7421">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="cref_801113801" id="ixv-7422">2026-04-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="cref_801113801" id="ixv-7423">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="cref_801113801" id="ixv-7424">000-40854</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_801113801" id="ixv-7425">NUTRIBAND INC.</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber contextRef="cref_801113801" id="ixv-7426">81-1118176</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="cref_801113801" id="ixv-7427">121 South Orange Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_801113801" id="ixv-7428">Suite 1500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="cref_801113801" id="ixv-7429">Orlando</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="cref_801113801" id="ixv-7430">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="cref_801113801" id="ixv-7431">32801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="cref_801113801" id="ixv-7432">(407)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_801113801" id="ixv-7433">377-6695</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="cref_1435951752" id="ixv-7434">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_1435951752" id="ixv-7435">NTRB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_1435951752" id="ixv-7436">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="cref_1473919857" id="ixv-7437">Warrants</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_1473919857" id="ixv-7438">NTRBW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_1473919857" id="ixv-7439">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="cref_801113801" id="ixv-7440">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_801113801" id="ixv-7441">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_801113801" id="ixv-7442">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="cref_801113801" id="ixv-7443">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="cref_801113801" id="ixv-7444">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="cref_801113801" id="ixv-7445">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="cref_801113801" id="ixv-7446">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_1733830422"
      decimals="0"
      id="ixv-7447"
      unitRef="uref_1142227404">12155983</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7448"
      unitRef="uref_1130380903">4006184</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7449"
      unitRef="uref_1130380903">4574857</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7450"
      unitRef="uref_1130380903">2632</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7451"
      unitRef="uref_1130380903">118404</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7452"
      unitRef="uref_1130380903">121494</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7453"
      unitRef="uref_1130380903">117987</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7454"
      unitRef="uref_1130380903">245952</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7455"
      unitRef="uref_1130380903">177470</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7456"
      unitRef="uref_1130380903">4376262</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7457"
      unitRef="uref_1130380903">4988718</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7458"
      unitRef="uref_1130380903">548244</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7459"
      unitRef="uref_1130380903">567255</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7460"
      unitRef="uref_1130380903">1719535</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7461"
      unitRef="uref_1130380903">1719535</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7462"
      unitRef="uref_1130380903">63000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7463"
      unitRef="uref_1130380903">72000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7464"
      unitRef="uref_1130380903">185261</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7465"
      unitRef="uref_1130380903">200427</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7466"
      unitRef="uref_1130380903">6892302</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7467"
      unitRef="uref_1130380903">7547935</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7468"
      unitRef="uref_1130380903">639192</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7469"
      unitRef="uref_1130380903">502654</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7470"
      unitRef="uref_1130380903">30406</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7471"
      unitRef="uref_1130380903">120303</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7472"
      unitRef="uref_1130380903">33201</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7473"
      unitRef="uref_1130380903">32453</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7474"
      unitRef="uref_1130380903">129338</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7475"
      unitRef="uref_1130380903">128871</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7476"
      unitRef="uref_1130380903">832137</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7477"
      unitRef="uref_1130380903">784281</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7478"
      unitRef="uref_1130380903">29825</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7479"
      unitRef="uref_1130380903">35861</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7480"
      unitRef="uref_1130380903">40350</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7481"
      unitRef="uref_1130380903">48305</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7482"
      unitRef="uref_1130380903">902312</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7483"
      unitRef="uref_1130380903">868447</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_1599877957"
      decimals="3"
      id="ixv-7484"
      unitRef="uref_1838883110">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_1726790181"
      decimals="3"
      id="ixv-7485"
      unitRef="uref_1838883110">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7486"
      unitRef="uref_1142227404">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7487"
      unitRef="uref_1142227404">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7488"
      unitRef="uref_1142227404">3008643</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7489"
      unitRef="uref_1142227404">3008643</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7490"
      unitRef="uref_1142227404">3008643</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7491"
      unitRef="uref_1142227404">3008643</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7492"
      unitRef="uref_1130380903">3009</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7493"
      unitRef="uref_1130380903">3009</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1599877957"
      decimals="3"
      id="ixv-7494"
      unitRef="uref_1838883110">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1726790181"
      decimals="3"
      id="ixv-7495"
      unitRef="uref_1838883110">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7496"
      unitRef="uref_1142227404">291666666</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7497"
      unitRef="uref_1142227404">291666666</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7498"
      unitRef="uref_1142227404">12174883</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7499"
      unitRef="uref_1142227404">12174883</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7500"
      unitRef="uref_1142227404">12155983</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7501"
      unitRef="uref_1142227404">12155983</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7502"
      unitRef="uref_1130380903">12156</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7503"
      unitRef="uref_1130380903">12156</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7504"
      unitRef="uref_1130380903">53996205</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7505"
      unitRef="uref_1130380903">53443747</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7506"
      unitRef="uref_1130380903">-304</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7507"
      unitRef="uref_1130380903">-304</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7508"
      unitRef="uref_1142227404">18900</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7509"
      unitRef="uref_1142227404">18900</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7510"
      unitRef="uref_1130380903">86852</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7511"
      unitRef="uref_1130380903">86852</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7512"
      unitRef="uref_1130380903">-47934224</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7513"
      unitRef="uref_1130380903">-46692268</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7514"
      unitRef="uref_1130380903">5989990</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7515"
      unitRef="uref_1130380903">6679488</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7516"
      unitRef="uref_1130380903">6892302</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7517"
      unitRef="uref_1130380903">7547935</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7518"
      unitRef="uref_1130380903">433399</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7519"
      unitRef="uref_1130380903">667432</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7520"
      unitRef="uref_1130380903">236598</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7521"
      unitRef="uref_1130380903">415451</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7522"
      unitRef="uref_1130380903">247261</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7523"
      unitRef="uref_1130380903">683426</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7524"
      unitRef="uref_1130380903">1203891</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7525"
      unitRef="uref_1130380903">982052</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7526"
      unitRef="uref_1130380903">1687750</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7527"
      unitRef="uref_1130380903">2080929</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7528"
      unitRef="uref_1130380903">-1254351</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7529"
      unitRef="uref_1130380903">-1413497</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7530"
      unitRef="uref_1130380903">17403</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7531"
      unitRef="uref_1130380903">30508</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpenseNonoperating
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7532"
      unitRef="uref_1130380903">5008</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7533"
      unitRef="uref_1130380903">5880</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7534"
      unitRef="uref_1130380903">12395</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7535"
      unitRef="uref_1130380903">24628</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7536"
      unitRef="uref_1130380903">-1241956</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7537"
      unitRef="uref_1130380903">-1388869</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7538"
      unitRef="uref_1130380903">-1241956</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7539"
      unitRef="uref_1130380903">-1388869</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7540"
      unitRef="uref_1130380903">-1241956</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7541"
      unitRef="uref_1130380903">-1241956</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7542"
      unitRef="uref_1130380903">-1388869</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7543"
      unitRef="uref_1130380903">-1388869</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_801113801"
      decimals="2"
      id="ixv-7544"
      unitRef="uref_1838883110">-0.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_801113801"
      decimals="2"
      id="ixv-7545"
      unitRef="uref_1838883110">-0.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1439619776"
      decimals="2"
      id="ixv-7546"
      unitRef="uref_1838883110">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1439619776"
      decimals="2"
      id="ixv-7547"
      unitRef="uref_1838883110">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7548"
      unitRef="uref_1142227404">12155983</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7549"
      unitRef="uref_1142227404">12155983</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7550"
      unitRef="uref_1142227404">11125800</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7551"
      unitRef="uref_1142227404">11125800</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7552"
      unitRef="uref_1130380903">6679488</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_962746945"
      decimals="0"
      id="ixv-7553"
      unitRef="uref_1142227404">12155983</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_962746945"
      decimals="0"
      id="ixv-7554"
      unitRef="uref_1130380903">12156</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_351299798"
      decimals="0"
      id="ixv-7555"
      unitRef="uref_1142227404">3008643</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_748811741"
      decimals="0"
      id="ixv-7556"
      unitRef="uref_1130380903">53443747</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_368771960"
      decimals="0"
      id="ixv-7557"
      unitRef="uref_1130380903">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1880985516"
      decimals="0"
      id="ixv-7558"
      unitRef="uref_1130380903">-46692268</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1926437787"
      decimals="0"
      id="ixv-7559"
      unitRef="uref_1130380903">-86852</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_801113801"
      decimals="0"
      id="fc_1433503560"
      unitRef="uref_1130380903">552458</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_311767850"
      decimals="0"
      id="fc_311767850"
      unitRef="uref_1130380903">552458</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7562"
      unitRef="uref_1130380903">-1241956</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1713273969"
      decimals="0"
      id="ixv-7563"
      unitRef="uref_1130380903">-1241956</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7564"
      unitRef="uref_1130380903">5989990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_711521113"
      decimals="0"
      id="ixv-7565"
      unitRef="uref_1142227404">12155983</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_711521113"
      decimals="0"
      id="ixv-7566"
      unitRef="uref_1130380903">12156</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_1365327810"
      decimals="0"
      id="ixv-7567"
      unitRef="uref_1142227404">3008643</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_960217129"
      decimals="0"
      id="ixv-7568"
      unitRef="uref_1130380903">53996205</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1303687185"
      decimals="0"
      id="ixv-7569"
      unitRef="uref_1130380903">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_847473816"
      decimals="0"
      id="ixv-7570"
      unitRef="uref_1130380903">-47934224</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1208939897"
      decimals="0"
      id="ixv-7571"
      unitRef="uref_1130380903">-86852</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_371919607"
      decimals="0"
      id="ixv-7572"
      unitRef="uref_1130380903">6428905</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_330268729"
      decimals="0"
      id="ixv-7573"
      unitRef="uref_1142227404">11074810</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_330268729"
      decimals="0"
      id="ixv-7574"
      unitRef="uref_1130380903">11075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1302239174"
      decimals="0"
      id="ixv-7575"
      unitRef="uref_1130380903">45029317</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1620482763"
      decimals="0"
      id="ixv-7576"
      unitRef="uref_1130380903">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_664487435"
      decimals="0"
      id="ixv-7577"
      unitRef="uref_1130380903">-38462636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_21334872"
      decimals="0"
      id="ixv-7578"
      unitRef="uref_1130380903">-148547</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7579"
      unitRef="uref_1130380903">63350</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_268181459"
      decimals="0"
      id="ixv-7580"
      unitRef="uref_1142227404">8500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_268181459"
      decimals="0"
      id="ixv-7581"
      unitRef="uref_1130380903">9</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1456873658"
      decimals="0"
      id="ixv-7582"
      unitRef="uref_1130380903">24496</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_16094978"
      decimals="0"
      id="ixv-7583"
      unitRef="uref_1130380903">38845</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ntrb:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="cref_268181459"
      decimals="0"
      id="ixv-7584"
      unitRef="uref_1142227404">46961</ntrb:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants
      contextRef="cref_268181459"
      decimals="0"
      id="ixv-7585"
      unitRef="uref_1130380903">46</ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants>
    <ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants
      contextRef="cref_1456873658"
      decimals="0"
      id="ixv-7586"
      unitRef="uref_1130380903">-46</ntrb:StockIssuedDuringThePeriodValueCashlessExerciseOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7587"
      unitRef="uref_1130380903">-1388869</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1683264468"
      decimals="0"
      id="ixv-7588"
      unitRef="uref_1130380903">-1388869</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="cref_1503019495"
      decimals="0"
      id="ixv-7589"
      unitRef="uref_1130380903">5103386</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_230100510"
      decimals="0"
      id="ixv-7590"
      unitRef="uref_1142227404">11130271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_230100510"
      decimals="0"
      id="ixv-7591"
      unitRef="uref_1130380903">11130</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_18426132"
      decimals="0"
      id="ixv-7592"
      unitRef="uref_1130380903">45053767</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_839495585"
      decimals="0"
      id="ixv-7593"
      unitRef="uref_1130380903">-304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1699890394"
      decimals="0"
      id="ixv-7594"
      unitRef="uref_1130380903">-39851505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1458803835"
      decimals="0"
      id="ixv-7595"
      unitRef="uref_1130380903">-109702</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7596"
      unitRef="uref_1130380903">-1241956</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7597"
      unitRef="uref_1130380903">-1388869</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7598"
      unitRef="uref_1130380903">34177</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7599"
      unitRef="uref_1130380903">57480</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseExpense
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7600"
      unitRef="uref_1130380903">9000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7601"
      unitRef="uref_1130380903">9000</us-gaap:OperatingLeaseExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7602"
      unitRef="uref_1130380903">63350</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7603"
      unitRef="uref_1130380903">552458</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7604"
      unitRef="uref_1130380903">-115772</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7605"
      unitRef="uref_1130380903">20289</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7606"
      unitRef="uref_1130380903">68483</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7607"
      unitRef="uref_1130380903">-40568</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7608"
      unitRef="uref_1130380903">3507</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7609"
      unitRef="uref_1130380903">3283</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7610"
      unitRef="uref_1130380903">-89897</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7611"
      unitRef="uref_1130380903">-111200</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7612"
      unitRef="uref_1130380903">-7207</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7613"
      unitRef="uref_1130380903">-6579</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7614"
      unitRef="uref_1130380903">136539</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7615"
      unitRef="uref_1130380903">22850</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7616"
      unitRef="uref_1130380903">-563104</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7617"
      unitRef="uref_1130380903">-1336972</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7618"
      unitRef="uref_1130380903">5324</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7619"
      unitRef="uref_1130380903">-5324</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7620"
      unitRef="uref_1130380903">5569</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7621"
      unitRef="uref_1130380903">5324</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7622"
      unitRef="uref_1130380903">-5569</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7623"
      unitRef="uref_1130380903">-5324</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7624"
      unitRef="uref_1130380903">-568673</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7625"
      unitRef="uref_1130380903">-1347620</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7626"
      unitRef="uref_1130380903">4574857</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_371919607"
      decimals="0"
      id="ixv-7627"
      unitRef="uref_1130380903">4311719</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7628"
      unitRef="uref_1130380903">4006184</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1503019495"
      decimals="0"
      id="ixv-7629"
      unitRef="uref_1130380903">2964099</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7630"
      unitRef="uref_1130380903">1250</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7631"
      unitRef="uref_1130380903">621</us-gaap:InterestPaidNet>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7632"
      unitRef="uref_1130380903">46</us-gaap:ConversionOfStockAmountIssued1>
    <ntrb:MeasurementOfOperatingLeaseRightofUseAssetsAndLiabilities
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7633"
      unitRef="uref_1130380903">108000</ntrb:MeasurementOfOperatingLeaseRightofUseAssetsAndLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="cref_801113801" id="ixv-2489">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;1.&lt;/td&gt; &lt;td style="text-align: justify"&gt;ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; Nutriband Inc. (the &#x201c;Company&#x201d;) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company&#x2019;s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; On August 1, 2018, the Company acquired 4P Therapeutics LLC (&#x201c;4P Therapeutics&#x201d;) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics was a director of the Company from April 2018, when the Company entered into an agreement to acquire 4P Therapeutics until he resigned as a director in January 2022. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;4P Therapeutics is engaged in the development of transdermal pharmaceutical products. With the acquisition of 4P Therapeutics, 4P Therapeutics&#x2019; drug development business became the Company&#x2019;s principal business. The primary focus of the business is to incorporate the Company&#x2019;s Aversa abuse deterrent technology into transdermal patches containing already approved drugs. Although these drugs are already approved, the Company needs to conduct a product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (&#x201c;Pocono Pharmaceuticals&#x201d;), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical businesses of Pocono Coated Products LLC (&#x201c;PCP&#x201d;). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (&#x201c;Active Intelligence&#x201d;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Pocono Pharmaceuticals is a coated products contract development and manufacturing organization that supports their customers with product design, development and manufacturing services. Pocono Pharmaceuticals has specialized expertise and state-of-the-art manufacturing capabilities for topical, transdermal and kinesiology tape products. Active Intelligence manufactures activated kinesiology tape for customers in the sports and physical markets.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="cref_801113801" id="ixv-7634">2016-01-04</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="cref_1480997135"
      decimals="0"
      id="ixv-7635"
      unitRef="uref_1130380903">2250000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_835892109"
      decimals="0"
      id="ixv-7636"
      unitRef="uref_1142227404">250000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="cref_1597596874"
      decimals="0"
      id="ixv-7637"
      unitRef="uref_1130380903">1850000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_1480997135"
      decimals="0"
      id="ixv-7638"
      unitRef="uref_1130380903">400000</us-gaap:CommonStockValue>
    <ntrb:RoyaltyPercentage
      contextRef="cref_1604186989"
      decimals="2"
      id="ixv-7639"
      unitRef="uref_490212018">0.06</ntrb:RoyaltyPercentage>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="cref_1319143949"
      decimals="2"
      id="ixv-7640"
      unitRef="uref_490212018">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_801113801" id="ixv-2511">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;2.&lt;/td&gt; &lt;td&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Unaudited Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;The consolidated balance sheet as of April 30, 2026, and the consolidated statements of operations, stockholders&#x2019; equity and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) to prepare fairly the financial position, results of operations and cash flows for all periods presented have been made. The results for the three months ending April 30, 2026, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with consolidated financial statements and footnotes therein included in Nutriband&#x2019;s Annual Report on Form 10-K for the year ending January 31, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (SEC&#x201d;). The preparation of consolidated statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and accompanying footnotes. Actual results could differ from estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;The Company&#x2019;s significant accounting policies are in Note 2 in the Company&#x2019;s Annual Report on Form 10-K for the ending January 31, 2026. There were no significant changes to these accounting policies during the three months ending April 30, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Going Concern Assessment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Management assesses liquidity and going concern uncertainty in the Company&#x2019;s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the &#x201c;look-forward period&#x201d;, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved, and management has the proper authority to execute them within the look-forward period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; As of April 30, 2026, the Company had cash and cash equivalents of $4,006,184 and working capital of $3,544,125. For the three months ended April 30, 2026, the Company incurred a net loss from operations of $1,254,351 and used cash flow from operations of $563,104. The Company has generated operating losses since its inception and has relied on sales of securities and the issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 17, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company&#x2019;s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors. During the year ended January 31, 2026, the Company received proceeds of $5,425,709 from the exercise of warrants and employee stock options. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Management has prepared estimates for operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company&#x2019;s ability to continue operations as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;In May 2014, the FASB issued ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606) (&#x201c;ASU 2014-09&#x201d;), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Types&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The following is a description of the Company&#x2019;s revenue types, which include professional services and sale of goods:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Product revenues derived from the sale of the Company&#x2019;s consumer transdermal, topical and tape products with sales listed under sale of goods.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Contract research and development services for pharmaceutical and medical device life sciences customers with revenues listed under services.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company&#x2019;s revenues include significant concentration from a limited number of customers. For the three months ended April 30, 2026, Customer A, Customer B, Customer C, and Customer D accounted for approximately 25%, 20%, 14%, and 10% of the Company&#x2019;s total consolidated revenues. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2.25pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2.25pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Performance Obligations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of accounts in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company&#x2019;s different revenue service types, the performance obligation is satisfied at different times. The Company&#x2019;s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;All revenue recognized in the income statement is considered to be revenue from contracts with customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Revenue by type:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%"&gt;Sale of goods&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1998475536"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1544052377"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Revenue by geographic location:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1587308201"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_137935760"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company&#x2019;s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company&#x2019;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. As of April 30, 2026 and January 31, 2026, Goodwill amounted to $1,719,535 and $1,719,535, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"&gt;The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company&#x2019;s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&#x2019;s financial management and certain standards are under consideration.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <ntrb:UnauditedFinancialStatementsPolicyTextBlock contextRef="cref_801113801" id="ixv-2519">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Unaudited Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;The consolidated balance sheet as of April 30, 2026, and the consolidated statements of operations, stockholders&#x2019; equity and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) to prepare fairly the financial position, results of operations and cash flows for all periods presented have been made. The results for the three months ending April 30, 2026, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with consolidated financial statements and footnotes therein included in Nutriband&#x2019;s Annual Report on Form 10-K for the year ending January 31, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (SEC&#x201d;). The preparation of consolidated statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and accompanying footnotes. Actual results could differ from estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt; text-align: justify"&gt;The Company&#x2019;s significant accounting policies are in Note 2 in the Company&#x2019;s Annual Report on Form 10-K for the ending January 31, 2026. There were no significant changes to these accounting policies during the three months ending April 30, 2026.&lt;/p&gt;</ntrb:UnauditedFinancialStatementsPolicyTextBlock>
    <ntrb:GoingConcernAssessmentPolicyPolicyTextBlock contextRef="cref_801113801" id="ixv-2538">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Going Concern Assessment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Management assesses liquidity and going concern uncertainty in the Company&#x2019;s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the &#x201c;look-forward period&#x201d;, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved, and management has the proper authority to execute them within the look-forward period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; As of April 30, 2026, the Company had cash and cash equivalents of $4,006,184 and working capital of $3,544,125. For the three months ended April 30, 2026, the Company incurred a net loss from operations of $1,254,351 and used cash flow from operations of $563,104. The Company has generated operating losses since its inception and has relied on sales of securities and the issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 17, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company&#x2019;s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors. During the year ended January 31, 2026, the Company received proceeds of $5,425,709 from the exercise of warrants and employee stock options. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Management has prepared estimates for operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company&#x2019;s ability to continue operations as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.&lt;/p&gt;</ntrb:GoingConcernAssessmentPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7641"
      unitRef="uref_1130380903">4006184</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ntrb:WorkingCapital
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7642"
      unitRef="uref_1130380903">3544125</ntrb:WorkingCapital>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7643"
      unitRef="uref_1130380903">-1254351</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7644"
      unitRef="uref_1130380903">-563104</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:LinesOfCreditCurrent
      contextRef="cref_1831155051"
      decimals="0"
      id="ixv-7645"
      unitRef="uref_1130380903">2000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="cref_1483634024"
      decimals="0"
      id="ixv-7646"
      unitRef="uref_1130380903">5000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="cref_323607820"
      decimals="0"
      id="ixv-7647"
      unitRef="uref_1130380903">8400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="cref_1330704236"
      decimals="0"
      id="ixv-7648"
      unitRef="uref_1130380903">5425709</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="cref_801113801" id="ixv-2559">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;In May 2014, the FASB issued ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606) (&#x201c;ASU 2014-09&#x201d;), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="cref_801113801" id="ixv-2566">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Revenue Types&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The following is a description of the Company&#x2019;s revenue types, which include professional services and sale of goods:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Product revenues derived from the sale of the Company&#x2019;s consumer transdermal, topical and tape products with sales listed under sale of goods.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Contract research and development services for pharmaceutical and medical device life sciences customers with revenues listed under services.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <ntrb:ContractsWithCustomersPolicyPolicyTextBlock contextRef="cref_801113801" id="ixv-2598">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company&#x2019;s revenues include significant concentration from a limited number of customers. For the three months ended April 30, 2026, Customer A, Customer B, Customer C, and Customer D accounted for approximately 25%, 20%, 14%, and 10% of the Company&#x2019;s total consolidated revenues. &lt;/p&gt;</ntrb:ContractsWithCustomersPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1928265586"
      decimals="2"
      id="ixv-7649"
      unitRef="uref_490212018">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1805760617"
      decimals="2"
      id="ixv-7650"
      unitRef="uref_490212018">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_438557598"
      decimals="2"
      id="ixv-7651"
      unitRef="uref_490212018">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1634907155"
      decimals="2"
      id="ixv-7652"
      unitRef="uref_490212018">0.10</us-gaap:ConcentrationRiskPercentage1>
    <ntrb:ContractLiabilitiesPolicyTextBlock contextRef="cref_801113801" id="ixv-2607">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2.25pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2.25pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.&lt;/p&gt;</ntrb:ContractLiabilitiesPolicyTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock contextRef="cref_801113801" id="ixv-2615">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Performance Obligations&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of accounts in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company&#x2019;s different revenue service types, the performance obligation is satisfied at different times. The Company&#x2019;s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;All revenue recognized in the income statement is considered to be revenue from contracts with customers.&lt;/p&gt;</us-gaap:RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock>
    <ntrb:DisaggregationOfRevenuesPolicyTextBlock contextRef="cref_801113801" id="ixv-2630">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Revenue by type:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%"&gt;Sale of goods&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1998475536"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1544052377"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Revenue by geographic location:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1587308201"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_137935760"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ntrb:DisaggregationOfRevenuesPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="cref_801113801" id="ixv-2635">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Revenue by type:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%"&gt;Sale of goods&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Services&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1998475536"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1544052377"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_722521170"
      decimals="0"
      id="ixv-7653"
      unitRef="uref_1130380903">433399</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1490037352"
      decimals="0"
      id="ixv-7654"
      unitRef="uref_1130380903">667432</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7655"
      unitRef="uref_1130380903">433399</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7656"
      unitRef="uref_1130380903">667432</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="cref_801113801" id="ixv-2699">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Revenue by geographic location:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1587308201"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_137935760"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1199660357"
      decimals="0"
      id="ixv-7657"
      unitRef="uref_1130380903">433399</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1438364266"
      decimals="0"
      id="ixv-7658"
      unitRef="uref_1130380903">667432</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7659"
      unitRef="uref_1130380903">433399</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7660"
      unitRef="uref_1130380903">667432</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="cref_801113801" id="ixv-2763">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company&#x2019;s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company&#x2019;s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. As of April 30, 2026 and January 31, 2026, Goodwill amounted to $1,719,535 and $1,719,535, respectively. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="cref_85067590"
      decimals="0"
      id="ixv-7661"
      unitRef="uref_1130380903">1719235</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="cref_1977080082"
      decimals="0"
      id="ixv-7662"
      unitRef="uref_1130380903">5810640</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7663"
      unitRef="uref_1130380903">1719535</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7664"
      unitRef="uref_1130380903">1719535</us-gaap:Goodwill>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="cref_801113801" id="ixv-2771">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"&gt;The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company&#x2019;s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&#x2019;s financial management and certain standards are under consideration.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="cref_801113801" id="ixv-2778">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;3.&lt;/td&gt; &lt;td&gt;PROPERTY AND EQUIPMENT&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;April 30,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;January 31,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,389,756&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,389,756&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Furniture and Fixtures&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 0in; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,553,984&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,553,984&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,005,740&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(986,729&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Property and Equipment&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;548,244&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;567,255&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt; Depreciation expenses amounted to $19,011 and $42,314 for the three months ended April 30, 2026, and 2025, respectively. During the three months ended April 30, 2026, and 2025, depreciation expenses of $15,208 and $33,851, respectively, have been allocated to the cost of goods sold. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="cref_801113801" id="ixv-2786">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;April 30,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;January 31,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;144,585&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,389,756&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,389,756&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Furniture and Fixtures&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,643&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 0in; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,553,984&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,553,984&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,005,740&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(986,729&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Property and Equipment&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;548,244&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;567,255&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1349139423"
      decimals="0"
      id="ixv-7665"
      unitRef="uref_1130380903">144585</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1446629769"
      decimals="0"
      id="ixv-7666"
      unitRef="uref_1130380903">144585</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_57195344"
      decimals="0"
      id="ixv-7667"
      unitRef="uref_1130380903">1389756</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_928023170"
      decimals="0"
      id="ixv-7668"
      unitRef="uref_1130380903">1389756</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_28000889"
      decimals="0"
      id="ixv-7669"
      unitRef="uref_1130380903">19643</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_49913731"
      decimals="0"
      id="ixv-7670"
      unitRef="uref_1130380903">19643</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7671"
      unitRef="uref_1130380903">1553984</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7672"
      unitRef="uref_1130380903">1553984</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7673"
      unitRef="uref_1130380903">1005740</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7674"
      unitRef="uref_1130380903">986729</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7675"
      unitRef="uref_1130380903">548244</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7676"
      unitRef="uref_1130380903">567255</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7677"
      unitRef="uref_1130380903">19011</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7678"
      unitRef="uref_1130380903">42314</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_1170331083"
      decimals="0"
      id="ixv-7679"
      unitRef="uref_1130380903">15208</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_1035181820"
      decimals="0"
      id="ixv-7680"
      unitRef="uref_1130380903">33851</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock contextRef="cref_801113801" id="ixv-2884">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;4.&lt;/td&gt; &lt;td&gt;NOTES PAYABLE&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="text-decoration:underline"&gt;Notes Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the three months ended April 30, 2026, the Company made $4,380 of principal payments. As of April 30, 2026, the amount due was $47,798, of which $17,973 is current. As of January 31, 2026, the amount due was $52,178. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of April 30, 2026, the amount due was $4,837, all of which is current. As of January 31, 2026, the amount due was $6,026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="text-decoration:underline"&gt;Note payable-related party.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility to the Company entered on March 17, 2023. Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. The Company received advances of $300,000 during the nine months ended October 31, 2024. On May 15, 2024, the Company agreed to convert the $300,000 debt. The conversion was made pursuant to the terms of a Conversion Agreement, which provided the conversion of $300,000 of principal and $4,922 of accrued interest. The Company issued 76,230 shares of common stock and 152,460 warrants exercisable at $6.43 per share, resulting in a $368,036 loss on extinguishment. As of April 30, 2026 and January 31, 2026 , the balance due was $-0- and $-0-, respectively. The Company recorded interest expense of $-0- and $-0- for the three months ended April 30, 2026, and 2025, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&lt;span style="text-decoration:underline"&gt;Secured borrowing liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; On July 19, 2023, the Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the three months ended April 30, 2026, and 2025, the Company recorded an interest expense of $2,549 and $2,549, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; Interest expenses for the three months ended April 30, 2026, and 2025, were $5,008 and $5,880, respectively. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCredit
      contextRef="cref_1972791219"
      decimals="0"
      id="ixv-7681"
      unitRef="uref_1130380903">160000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="cref_241892646" id="ixv-7682">2028-10-16</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="cref_241892646"
      decimals="2"
      id="ixv-7683"
      unitRef="uref_490212018">0.05</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="cref_1972791219"
      decimals="0"
      id="ixv-7684"
      unitRef="uref_1130380903">139184</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="cref_241892646"
      decimals="0"
      id="ixv-7685"
      unitRef="uref_1130380903">1697</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCreditFacilityAnnualPrincipalPayment
      contextRef="cref_241892646"
      decimals="0"
      id="ixv-7686"
      unitRef="uref_1130380903">4380</us-gaap:LineOfCreditFacilityAnnualPrincipalPayment>
    <us-gaap:NotesPayable
      contextRef="cref_1972791219"
      decimals="0"
      id="ixv-7687"
      unitRef="uref_1130380903">47798</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="cref_1972791219"
      decimals="0"
      id="ixv-7688"
      unitRef="uref_1130380903">17973</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayable
      contextRef="cref_888680957"
      decimals="0"
      id="ixv-7689"
      unitRef="uref_1130380903">52178</us-gaap:NotesPayable>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="cref_1865326699"
      decimals="0"
      id="ixv-7690"
      unitRef="uref_1130380903">32274</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="cref_1865326699"
      decimals="0"
      id="ixv-7691"
      unitRef="uref_1130380903">22795</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="cref_1865326699"
      decimals="4"
      id="ixv-7692"
      unitRef="uref_490212018">0.0295</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="cref_1492224421"
      decimals="0"
      id="ixv-7693"
      unitRef="uref_1130380903">410</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:NotesPayable
      contextRef="cref_852992327"
      decimals="0"
      id="ixv-7694"
      unitRef="uref_1130380903">4837</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="cref_1688693998"
      decimals="0"
      id="ixv-7695"
      unitRef="uref_1130380903">6026</us-gaap:NotesPayable>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="cref_979954947"
      decimals="0"
      id="fc_979954947"
      unitRef="uref_1130380903">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="cref_864861034"
      decimals="2"
      id="ixv-7697"
      unitRef="uref_490212018">0.07</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="cref_315045102"
      decimals="0"
      id="ixv-7698"
      unitRef="uref_1130380903">300000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ConvertibleDebt
      contextRef="cref_1302937178"
      decimals="0"
      id="ixv-7699"
      unitRef="uref_1130380903">300000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="cref_882060044"
      decimals="0"
      id="ixv-7700"
      unitRef="uref_1130380903">300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="cref_882060044"
      decimals="0"
      id="ixv-7701"
      unitRef="uref_1130380903">4922</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1925245410"
      decimals="0"
      id="ixv-7702"
      unitRef="uref_1142227404">76230</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1925245410"
      decimals="0"
      id="ixv-7703"
      unitRef="uref_1142227404">152460</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1925245410"
      decimals="2"
      id="ixv-7704"
      unitRef="uref_1838883110">6.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="cref_882060044"
      decimals="0"
      id="ixv-7705"
      unitRef="uref_1130380903">368036</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNotesPayable
      contextRef="cref_1925245410"
      decimals="0"
      id="ixv-7706"
      unitRef="uref_1130380903">0</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="cref_1931587099"
      decimals="0"
      id="ixv-7707"
      unitRef="uref_1130380903">0</us-gaap:OtherNotesPayable>
    <us-gaap:InterestExpense
      contextRef="cref_882060044"
      decimals="0"
      id="ixv-7708"
      unitRef="uref_1130380903">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="cref_1625861207"
      decimals="0"
      id="ixv-7709"
      unitRef="uref_1130380903">0</us-gaap:InterestExpense>
    <us-gaap:NotesAndLoansPayable
      contextRef="cref_341012551"
      decimals="0"
      id="ixv-7710"
      unitRef="uref_1130380903">106528</us-gaap:NotesAndLoansPayable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="cref_280601010"
      decimals="2"
      id="ixv-7711"
      unitRef="uref_490212018">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpenseDebt
      contextRef="cref_280601010"
      decimals="0"
      id="ixv-7712"
      unitRef="uref_1130380903">2549</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="cref_215442559"
      decimals="0"
      id="ixv-7713"
      unitRef="uref_1130380903">2549</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7714"
      unitRef="uref_1130380903">5008</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7715"
      unitRef="uref_1130380903">5880</us-gaap:InterestExpenseDebt>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="cref_801113801" id="ixv-2911">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;5.&lt;/td&gt; &lt;td&gt;INTANGIBLE ASSETS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;As of April 30, 2026 and January 31, 2026, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;April 30,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;January 3,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Customer base&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;214,640&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;214,640&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intellectual property and trademarks&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;623,822&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;623,822&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;838,462&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;838,462&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(653,201&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(638,035&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Intangible Assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185,261&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;200,427&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt; Amortization expenses for the three months ended April 30, 2026 and 2025 amounted to $15,166 and $113,150, respectively. There was &lt;span style="-sec-ix-hidden:fc_1489173357"&gt;no&lt;/span&gt; impairment charges during the three months ended April 30, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: left"&gt;Year Ended January 31,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 88%; text-align: left"&gt;2027&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;45,500&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;2028&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;60,666&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;2029&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;41,736&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;2030&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;23,596&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;2031&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;13,763&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185,261&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="cref_801113801" id="ixv-2919">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;As of April 30, 2026 and January 31, 2026, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;April 30,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;January 3,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left"&gt;Customer base&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;214,640&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;214,640&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intellectual property and trademarks&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;623,822&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;623,822&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;838,462&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;838,462&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated amortization&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(653,201&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(638,035&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net Intangible Assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185,261&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;200,427&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1651249766"
      decimals="0"
      id="ixv-7716"
      unitRef="uref_1130380903">214640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_122751182"
      decimals="0"
      id="ixv-7717"
      unitRef="uref_1130380903">214640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1856764558"
      decimals="0"
      id="ixv-7718"
      unitRef="uref_1130380903">623822</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_2041513663"
      decimals="0"
      id="ixv-7719"
      unitRef="uref_1130380903">623822</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7720"
      unitRef="uref_1130380903">838462</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7721"
      unitRef="uref_1130380903">838462</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7722"
      unitRef="uref_1130380903">653201</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7723"
      unitRef="uref_1130380903">638035</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7724"
      unitRef="uref_1130380903">185261</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="cref_1726790181"
      decimals="0"
      id="ixv-7725"
      unitRef="uref_1130380903">200427</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="cref_801113801" id="ixv-3008">Amortization expenses for the three months ended April 30, 2026 and 2025 amounted to $15,166 and $113,150, respectively. There was &lt;span style="-sec-ix-hidden:fc_1489173357"&gt;no&lt;/span&gt; impairment charges during the three months ended April 30, 2026.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: left"&gt;Year Ended January 31,&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 88%; text-align: left"&gt;2027&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;45,500&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;2028&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;60,666&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;2029&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;41,736&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;2030&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;23,596&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;2031&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;13,763&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185,261&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7726"
      unitRef="uref_1130380903">15166</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7727"
      unitRef="uref_1130380903">113150</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="cref_1599877957"
      decimals="0"
      id="fc_888877284"
      unitRef="uref_1130380903">45500</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="cref_1599877957"
      decimals="0"
      id="fc_1854713953"
      unitRef="uref_1130380903">60666</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="cref_1599877957"
      decimals="0"
      id="fc_866864062"
      unitRef="uref_1130380903">41736</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="cref_1599877957"
      decimals="0"
      id="fc_23861436"
      unitRef="uref_1130380903">23596</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="cref_1599877957"
      decimals="0"
      id="fc_837488458"
      unitRef="uref_1130380903">13763</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7733"
      unitRef="uref_1130380903">185261</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="cref_801113801" id="ixv-3061">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;6.&lt;/td&gt; &lt;td&gt;RELATED PARTY TRANSACTIONS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Activity during the three months ended April 30, 2026&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;a)&lt;/td&gt; &lt;td style="text-align: justify"&gt;During the three months ended April 30, 2026, a director of the Company and a related party were issued warrants to purchase 206,080 shares of common stock at an exercise price of $3.73 per share.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Activity during the three months ended April 30, 2025&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;a)&lt;/td&gt; &lt;td style="text-align: justify"&gt;There were &lt;span style="-sec-ix-hidden:fc_1660144407"&gt;no&lt;/span&gt; related party transactions during the three months ended April 30, 2025.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7734"
      unitRef="uref_1142227404">206080</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="cref_138024624"
      decimals="2"
      id="ixv-7735"
      unitRef="uref_1838883110">3.73</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_801113801" id="ixv-3088">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;7.&lt;/td&gt; &lt;td&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="text-decoration:underline"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On July 9,2025, the board of directors created a series of non-voting preferred stock consisting initially of shares designated as the Series A Convertible Preferred Stock (the &#x201c;the Series A Preferred Stock&#x201d;). The terms of the Series A Preferred Stock provide that, following the date of the approval for commercial sale by the Federal Drug Administration of the Company&#x2019;s transdermal pharmaceutical products that are based on the Company&#x2019;s AVERSA abuse deterrent technology, each share of Series A Preferred Stock will be convertible at the option of the holder into one share of Common Stock. The holders of Series A Preferred Stock that do not convert their shares shall be eligible for dividends as declared by the board of directors for those holders of the Series A Preferred Stock, and the Series A Preferred Stock is also eligible for dividends declared by the board of directors on the class of common stock. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company authorized on July 9, 2025, a preferred stock dividend to be issued by the Company to all shareholders on the basis of one share of Series A Preferred stock issued for each four shares of common stock owned by the holder. The record date for the dividend was July 25, 2025. On the date of distribution of the dividend, 3,008,643 shares of the Series A Preferred Stock were issued to our shareholders. The fair value of the preferred stock dividend was $21,814,166. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="text-decoration:underline"&gt;Activity during the Three Months Ended April 30, 2026&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;(a)&lt;/td&gt; &lt;td&gt;There were no stock transactions during the three months ending April 30, 2026.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="text-decoration:underline"&gt;Activity during the Three Months Ended April 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 38.4pt"&gt;&lt;/td&gt; &lt;td style="width: 18pt"&gt;(a)&lt;/td&gt; &lt;td&gt;As of April 30, 2025, the Company held 23,900 shares of treasury stock. On March 4, 2025, 3,500 shares of treasury stock held by the Company were issued to employees for services rendered. The Company recorded an expense of $24,360 during the three months ending April 30, 2025, in connection with the transaction.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.4pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 38.4pt"&gt;&lt;/td&gt; &lt;td style="width: 18pt"&gt;(b)&lt;/td&gt; &lt;td&gt;On February 8, 2025, the Company entered into an agreement with a consultant to provide consulting services to the Company&#x2019;s Board of Directors. The Company issued 5,000 shares of the Company&#x2019;s common stock to the consultant, valued at $39,050 and expensed during the three months ending April 30, 2025. The shares were issued from the treasury shares held by the Company. The term of the agreement is for twelve months.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.4pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 38.4pt"&gt;&lt;/td&gt; &lt;td style="width: 18pt"&gt;(c)&lt;/td&gt; &lt;td&gt;In February 2025, the Company&#x2019;s outside counsel exercised 58,433 warrants as a cashless conversion and the Company issued 46,961 shares of common stock.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_747260730"
      decimals="0"
      id="ixv-7736"
      unitRef="uref_1142227404">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_747260730"
      decimals="3"
      id="ixv-7737"
      unitRef="uref_1838883110">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="cref_1068088003"
      decimals="0"
      id="ixv-7738"
      unitRef="uref_1142227404">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_1625954283"
      decimals="0"
      id="ixv-7739"
      unitRef="uref_1142227404">1</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1659322823"
      decimals="0"
      id="ixv-7740"
      unitRef="uref_1142227404">4</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockDividendsShares
      contextRef="cref_470460901"
      decimals="0"
      id="ixv-7741"
      unitRef="uref_1142227404">3008643</us-gaap:PreferredStockDividendsShares>
    <us-gaap:DividendsPreferredStock
      contextRef="cref_959351278"
      decimals="0"
      id="ixv-7742"
      unitRef="uref_1130380903">21814166</us-gaap:DividendsPreferredStock>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="cref_671162616" id="ixv-7743">7-for-6 forward stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_894328472"
      decimals="0"
      id="ixv-7744"
      unitRef="uref_1142227404">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_501121315"
      decimals="0"
      id="ixv-7745"
      unitRef="uref_1142227404">291666666</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:TreasuryStockCommonShares
      contextRef="cref_1503019495"
      decimals="0"
      id="ixv-7746"
      unitRef="uref_1142227404">23900</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="cref_180139111"
      decimals="0"
      id="ixv-7747"
      unitRef="uref_1142227404">3500</us-gaap:TreasuryStockCommonShares>
    <ntrb:TransactionExpense
      contextRef="cref_1439619776"
      decimals="0"
      id="ixv-7748"
      unitRef="uref_1130380903">24360</ntrb:TransactionExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_357220360"
      decimals="0"
      id="fc_2115704126"
      unitRef="uref_1142227404">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_357220360"
      decimals="0"
      id="fc_357220360"
      unitRef="uref_1130380903">39050</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ntrb:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="cref_603781419"
      decimals="0"
      id="ixv-7751"
      unitRef="uref_1142227404">58433</ntrb:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_603781419"
      decimals="0"
      id="ixv-7752"
      unitRef="uref_1142227404">46961</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ntrb:OptionsAndWarrantsTextBlock contextRef="cref_801113801" id="ixv-3150">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;8.&lt;/td&gt; &lt;td&gt;OPTIONS and WARRANTS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; In September 2025, the Company issued 340,393 warrants to investors for services rendered, including a director and a related party of the Company. The warrants are exercisable at a price of $6.00 per share and expire three years from the date of issuance. The Company recorded a non-cash expense of $1,250,264 during the year ended January 31, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company used the Black Scholes valuation model to record fair value of the warrants issued during the year ending January 31, 2026. The valuation model used a dividend rate of 0%; expected terms of 2.5 years; volatility rates of 105%; and risk-free rate of 4%. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; In March 2026, the Company issued 340,393 warrants to investors for services rendered, including a director and a related party of the Company. The warrants vested immediately and are exercisable at a price of $3.73 per share and expire three years from the date of issuance. The Company recorded a non-cash expense of $552,458 during the three months ended April 30, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company used the Black Scholes valuation model to record fair value of the warrants issued during the three months ending April 30, 2026. The valuation model used a dividend rate of 0%; expected terms of 1.5 years: volatility rates of 90%; and risk-free rate of 3,7%. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes the changes in the outstanding warrants and the related price of the shares of the common stock issued to non-employees of the Company during the years ended January 31, 2026 and 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Remaining&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Intrinsic&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Life&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 53%"&gt;Outstanding, January 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;5,546,973&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;5.89&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center"&gt;3.68 years&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_869578959"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3.22 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_32178986"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1572536866"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1596153309"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_848963775"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(982,010&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.16&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_322993075"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Outstanding, January 31, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,905,356&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.39&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3.68 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1299203692"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.98 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1256447394"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1996307492"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1185320018"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1357309342"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1249219985"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1768809550"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_420593725"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Outstanding - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;2.98&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;2.98&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The following table summarizes additional information relating to the warrants outstanding as of April 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range of&lt;br/&gt;  Exercise&lt;br/&gt; Prices&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Remaining Contractual&lt;br/&gt; Life (Years)&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;br/&gt; for Shares Outstanding&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;br/&gt; for Shares Exercisable&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: center"&gt;4.37&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.77&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_677907702"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;4.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1238136706"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.43&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,509,963&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.45&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.43&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,509,963&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.43&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_432079429"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;1.53&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1780239855"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.39&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.39&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Option&lt;/span&gt;s&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the &#x201c;Plan&#x201d;). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (&#x201c;ISO&#x2019;s&#x201d;) under Section 422 of the Internal Revenue Code of 1986 (the &#x201c;Code&#x201d;) or which are not (&#x201c;non-ISO&#x2019;s&#x201d;) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as &#x201c;independent&#x201d; under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On March 20, 2024, our Board of Directors adopted an amendment to the Company&#x2019;s Employee Stock Option Plan (the &#x201c;Plan&#x201d;) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the &#x201c;Amendment&#x201d;). The Company submitted the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. The Amendment was approved by the stockholders on January 23, 2025. As of January 31, 2026, with the February 1, 2025, automatic issuance of shares available under the Plan, 56,082 shares remain available for issuance of options under the Plan. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; During the year ending January 31, 2026, 454,814 options to purchase shares of the Company&#x2019;s common stock were issued to executive officers and employees at prices of $5.47- $6.85 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued amounted to $1,383,732 and were recorded during the year ending January 31, 2026. The Company used the Black Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 96.55 %-108.35%; and a risk-free rate of 3.65%-3.91%. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes the changes in outstanding options and the related price of the shares of the Company&#x2019;s common stock issued to employees of the Company. See Note 6 for the issuance of related party options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Remaining&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Intrinsic&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Life&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%"&gt;Outstanding, January 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;1,373,668&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3.23&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center"&gt;1.90 years&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_140760890"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;454,834&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.35&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.90 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1297631516"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;(234,584&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1124983472"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(160,055&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.46&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Outstanding, January 31, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,433,863&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.23&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.90 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1083646122"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_911683903"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1854691229"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;(30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.98&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1243908151"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1995491074"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Outstanding - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.58&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;1.42&#160;&#160;&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,923&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.58&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;1.42&#160;&#160;&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,923&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes additional information relating to the options outstanding as of April 30, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Range of&lt;br/&gt;  Exercise&lt;br/&gt; Prices&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Life (Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;br/&gt; for Shares     Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;br/&gt; for Shares     Exercisable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;1.93&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;206,945&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: center"&gt;0.49&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;1.93&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;206,945&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;1.93&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;401,473&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.12&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;70,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.49&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.12&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;70,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.12&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;122,500&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;182,500&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.88&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;182,500&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;273,750&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.61&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.88&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.61&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.61&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;214,200&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.39&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;24,400&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.76&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;33,600&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.47&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;45,667&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.47&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;45,667&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.47&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1710946861"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.99&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.17&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.99&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.99&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_193294681"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;260,833&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.31&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;260,833&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1209449450"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.84&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;108,334&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.31&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.84&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;108,334&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.84&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_478459098"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.85&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;40,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.29&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.85&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;40,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.85&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1651616215"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;7.34&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;180,918&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.73&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;7.34&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;180,918&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;7.34&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_15631382"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.07&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1.73&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8.07&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8.07&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2015684357"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;1.42&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.57&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.57&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,923&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ntrb:OptionsAndWarrantsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1786324445"
      decimals="0"
      id="ixv-7753"
      unitRef="uref_1142227404">340393</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1786324445"
      decimals="2"
      id="ixv-7754"
      unitRef="uref_1838883110">6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="cref_1786324445" id="ixv-7755">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1330704236"
      decimals="0"
      id="ixv-7756"
      unitRef="uref_1130380903">1250264</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1330704236"
      decimals="2"
      id="ixv-7757"
      unitRef="uref_490212018">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1330704236" id="ixv-7758">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1330704236"
      decimals="2"
      id="ixv-7759"
      unitRef="uref_490212018">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1330704236"
      decimals="2"
      id="ixv-7760"
      unitRef="uref_490212018">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1375090296"
      decimals="0"
      id="ixv-7761"
      unitRef="uref_1142227404">340393</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1375090296"
      decimals="2"
      id="ixv-7762"
      unitRef="uref_1838883110">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="cref_1375090296" id="ixv-7763">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1685331535"
      decimals="0"
      id="ixv-7764"
      unitRef="uref_1130380903">552458</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1685331535"
      decimals="2"
      id="ixv-7765"
      unitRef="uref_490212018">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1685331535" id="ixv-7766">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1685331535"
      decimals="2"
      id="ixv-7767"
      unitRef="uref_490212018">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1685331535"
      decimals="2"
      id="ixv-7768"
      unitRef="uref_490212018">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="cref_801113801" id="ixv-3175">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes the changes in the outstanding warrants and the related price of the shares of the common stock issued to non-employees of the Company during the years ended January 31, 2026 and 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Remaining&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Intrinsic&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Life&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 53%"&gt;Outstanding, January 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;5,546,973&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;5.89&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center"&gt;3.68 years&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_869578959"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3.22 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_32178986"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1572536866"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1596153309"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_848963775"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(982,010&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.16&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_322993075"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Outstanding, January 31, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,905,356&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.39&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3.68 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1299203692"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.98 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1256447394"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1996307492"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1185320018"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1357309342"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1249219985"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1768809550"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_420593725"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Outstanding - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;2.98&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;2.98&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="cref_952288185"
      decimals="0"
      id="ixv-7769"
      unitRef="uref_1142227404">5546973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="cref_952288185"
      decimals="2"
      id="ixv-7770"
      unitRef="uref_1838883110">5.89</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeOutstandingBalance contextRef="cref_35834288" id="ixv-7771">P3Y8M4D</ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeOutstandingBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="cref_1330704236"
      decimals="0"
      id="ixv-7772"
      unitRef="uref_1142227404">340393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="cref_1330704236"
      decimals="2"
      id="ixv-7773"
      unitRef="uref_1838883110">6</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeGranted contextRef="cref_1330704236" id="ixv-7774">P3Y2M19D</ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="cref_1330704236"
      decimals="0"
      id="ixv-7775"
      unitRef="uref_1142227404">982010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="cref_1330704236"
      decimals="2"
      id="ixv-7776"
      unitRef="uref_1838883110">6.16</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="cref_794142459"
      decimals="0"
      id="ixv-7777"
      unitRef="uref_1142227404">4905356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="cref_794142459"
      decimals="2"
      id="ixv-7778"
      unitRef="uref_1838883110">6.39</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeOutstandingBalance contextRef="cref_1330704236" id="ixv-7779">P3Y8M4D</ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeOutstandingBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="cref_1685331535"
      decimals="0"
      id="ixv-7780"
      unitRef="uref_1142227404">340393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="cref_1685331535"
      decimals="2"
      id="ixv-7781"
      unitRef="uref_1838883110">3.73</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="cref_639260467"
      decimals="0"
      id="ixv-7782"
      unitRef="uref_1142227404">5245749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="cref_639260467"
      decimals="2"
      id="ixv-7783"
      unitRef="uref_1838883110">6.22</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeOutstandingBalance contextRef="cref_1685331535" id="ixv-7784">P2Y11M23D</ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeOutstandingBalance>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsntrinsicValueOutstandingBalance
      contextRef="cref_639260467"
      decimals="0"
      id="ixv-7785"
      unitRef="uref_1130380903">47655</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsntrinsicValueOutstandingBalance>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="cref_639260467"
      decimals="0"
      id="ixv-7786"
      unitRef="uref_1142227404">5245749</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisePriceExercisable
      contextRef="cref_639260467"
      decimals="2"
      id="ixv-7787"
      unitRef="uref_1838883110">6.22</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisePriceExercisable>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeExercisable contextRef="cref_1685331535" id="ixv-7788">P2Y11M23D</ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsRemainingLifeExercisable>
    <ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExercisable
      contextRef="cref_639260467"
      decimals="0"
      id="ixv-7789"
      unitRef="uref_1130380903">47655</ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIntrinsicValueExercisable>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="cref_801113801" id="ixv-3546">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The following table summarizes additional information relating to the warrants outstanding as of April 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range of&lt;br/&gt;  Exercise&lt;br/&gt; Prices&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Remaining Contractual&lt;br/&gt; Life (Years)&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;br/&gt; for Shares Outstanding&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;br/&gt; for Shares Exercisable&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: center"&gt;4.37&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;3.73&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.77&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_677907702"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;4.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;340,393&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.00&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1238136706"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.43&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,509,963&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.45&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.43&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;4,509,963&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.43&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_432079429"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;1.53&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1780239855"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.39&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,245,749&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.39&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,655&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_2002267615"
      decimals="0"
      id="ixv-7790"
      unitRef="uref_1142227404">340393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="cref_392548195" id="ixv-7791">P4Y4M13D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_2002267615"
      decimals="2"
      id="ixv-7792"
      unitRef="uref_1838883110">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_2002267615"
      decimals="0"
      id="ixv-7793"
      unitRef="uref_1142227404">340393</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="cref_2002267615"
      decimals="2"
      id="ixv-7794"
      unitRef="uref_1838883110">3.73</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="cref_2002267615"
      decimals="0"
      id="ixv-7795"
      unitRef="uref_1130380903">47655</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_708812864"
      decimals="0"
      id="ixv-7796"
      unitRef="uref_1142227404">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="cref_1553198873" id="ixv-7797">P2Y9M7D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_708812864"
      decimals="2"
      id="ixv-7798"
      unitRef="uref_1838883110">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_708812864"
      decimals="0"
      id="ixv-7799"
      unitRef="uref_1142227404">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="cref_708812864"
      decimals="2"
      id="ixv-7800"
      unitRef="uref_1838883110">4</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_483198360"
      decimals="0"
      id="ixv-7801"
      unitRef="uref_1142227404">340393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="cref_864234884" id="ixv-7802">P4Y4M13D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_483198360"
      decimals="2"
      id="ixv-7803"
      unitRef="uref_1838883110">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_483198360"
      decimals="0"
      id="ixv-7804"
      unitRef="uref_1142227404">340393</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="cref_483198360"
      decimals="2"
      id="ixv-7805"
      unitRef="uref_1838883110">6</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_1231422266"
      decimals="0"
      id="ixv-7806"
      unitRef="uref_1142227404">4509963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="cref_1933317982" id="ixv-7807">P2Y5M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_1231422266"
      decimals="2"
      id="ixv-7808"
      unitRef="uref_1838883110">6.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1231422266"
      decimals="0"
      id="ixv-7809"
      unitRef="uref_1142227404">4509963</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="cref_1231422266"
      decimals="2"
      id="ixv-7810"
      unitRef="uref_1838883110">6.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_1162610843"
      decimals="0"
      id="ixv-7811"
      unitRef="uref_1142227404">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="cref_327320294" id="ixv-7812">P1Y6M10D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_1162610843"
      decimals="2"
      id="ixv-7813"
      unitRef="uref_1838883110">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1162610843"
      decimals="0"
      id="ixv-7814"
      unitRef="uref_1142227404">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="cref_1162610843"
      decimals="2"
      id="ixv-7815"
      unitRef="uref_1838883110">7.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_639260467"
      decimals="0"
      id="ixv-7816"
      unitRef="uref_1142227404">5245749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_639260467"
      decimals="2"
      id="ixv-7817"
      unitRef="uref_1838883110">6.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_639260467"
      decimals="0"
      id="ixv-7818"
      unitRef="uref_1142227404">5245749</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="cref_639260467"
      decimals="2"
      id="ixv-7819"
      unitRef="uref_1838883110">6.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="cref_639260467"
      decimals="0"
      id="ixv-7820"
      unitRef="uref_1130380903">47655</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1602551012"
      decimals="0"
      id="ixv-7821"
      unitRef="uref_1142227404">408333</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="cref_1506999862"
      decimals="0"
      id="ixv-7822"
      unitRef="uref_1142227404">233333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="cref_988379700"
      decimals="0"
      id="ixv-7823"
      unitRef="uref_1142227404">233333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="cref_1328715614" id="ixv-7824">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_10807001"
      decimals="0"
      id="ixv-7825"
      unitRef="uref_1142227404">408333</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated
      contextRef="cref_1974626520"
      decimals="0"
      id="ixv-7826"
      unitRef="uref_1142227404">875000</us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated>
    <us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated
      contextRef="cref_385813736"
      decimals="0"
      id="ixv-7827"
      unitRef="uref_1142227404">1400000</us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_1780810116"
      decimals="0"
      id="ixv-7828"
      unitRef="uref_1142227404">56082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="cref_1381066858"
      decimals="0"
      id="ixv-7829"
      unitRef="uref_1142227404">454814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharePrice
      contextRef="cref_1186377537"
      decimals="2"
      id="ixv-7830"
      unitRef="uref_1838883110">5.47</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="cref_341740768"
      decimals="2"
      id="ixv-7831"
      unitRef="uref_1838883110">6.85</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="cref_1381066858" id="ixv-7832">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="cref_1381066858"
      decimals="0"
      id="ixv-7833"
      unitRef="uref_1130380903">1383732</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1381066858"
      decimals="2"
      id="ixv-7834"
      unitRef="uref_490212018">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1381066858" id="ixv-7835">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1938127607"
      decimals="4"
      id="ixv-7836"
      unitRef="uref_490212018">0.9655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1753317030"
      decimals="4"
      id="ixv-7837"
      unitRef="uref_490212018">1.0835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1938127607"
      decimals="4"
      id="ixv-7838"
      unitRef="uref_490212018">0.0365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1753317030"
      decimals="4"
      id="ixv-7839"
      unitRef="uref_490212018">0.0391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="cref_801113801" id="fc_737720133">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes the changes in outstanding options and the related price of the shares of the Company&#x2019;s common stock issued to employees of the Company. See Note 6 for the issuance of related party options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Remaining&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;Intrinsic&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Life&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 52%"&gt;Outstanding, January 31, 2025&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;1,373,668&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3.23&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center"&gt;1.90 years&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_140760890"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;454,834&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.35&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.90 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1297631516"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;(234,584&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1124983472"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(160,055&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.46&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Outstanding, January 31, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,433,863&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.23&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.90 years&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1083646122"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_911683903"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1854691229"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Expired/Cancelled&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;(30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;3.98&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;-&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1243908151"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1995491074"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Outstanding - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.58&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;1.42&#160;&#160;&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,923&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Exercisable - April 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.58&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;1.42&#160;&#160;&#160;years&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,923&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1815088329"
      decimals="0"
      id="ixv-7840"
      unitRef="uref_1142227404">1373668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1815088329"
      decimals="2"
      id="ixv-7841"
      unitRef="uref_1838883110">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_864283349" id="ixv-7842">P1Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_540884474"
      decimals="0"
      id="ixv-7843"
      unitRef="uref_1142227404">454834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_540884474"
      decimals="2"
      id="ixv-7844"
      unitRef="uref_1838883110">6.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted contextRef="cref_540884474" id="ixv-7845">P1Y10M24D</ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="cref_540884474"
      decimals="0"
      id="ixv-7846"
      unitRef="uref_1142227404">234584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_540884474"
      decimals="0"
      id="ixv-7847"
      unitRef="uref_1142227404">160055</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="cref_540884474"
      decimals="2"
      id="ixv-7848"
      unitRef="uref_1838883110">1.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1395898379"
      decimals="0"
      id="ixv-7849"
      unitRef="uref_1142227404">1433863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1395898379"
      decimals="2"
      id="ixv-7850"
      unitRef="uref_1838883110">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_540884474" id="ixv-7851">P1Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="cref_601733390"
      decimals="0"
      id="ixv-7852"
      unitRef="uref_1142227404">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="cref_601733390"
      decimals="2"
      id="ixv-7853"
      unitRef="uref_1838883110">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_455166402"
      decimals="0"
      id="ixv-7854"
      unitRef="uref_1142227404">1403863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_455166402"
      decimals="2"
      id="ixv-7855"
      unitRef="uref_1838883110">4.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_601733390" id="ixv-7856">P1Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_455166402"
      decimals="0"
      id="ixv-7857"
      unitRef="uref_1130380903">1069923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_455166402"
      decimals="0"
      id="ixv-7858"
      unitRef="uref_1142227404">1403863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_455166402"
      decimals="2"
      id="ixv-7859"
      unitRef="uref_1838883110">4.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_601733390" id="ixv-7860">P1Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_455166402"
      decimals="0"
      id="ixv-7861"
      unitRef="uref_1130380903">1069923</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="cref_801113801" id="ixv-4175">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table summarizes additional information relating to the options outstanding as of April 30, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Range of&lt;br/&gt;  Exercise&lt;br/&gt; Prices&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Life (Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;br/&gt; for Shares     Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;br/&gt; for Shares     Exercisable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;1.93&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;206,945&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 12%; text-align: center"&gt;0.49&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;1.93&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;206,945&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;1.93&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;401,473&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.12&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;70,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.49&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.12&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;70,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.12&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;122,500&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;182,500&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.88&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;182,500&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.37&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;273,750&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.61&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.88&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.61&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;170,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.61&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;214,200&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.39&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;20,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.65&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;24,400&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.76&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;33,600&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.47&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;45,667&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.75&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.47&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;45,667&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.47&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1710946861"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.99&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.17&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.99&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;30,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;5.99&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_193294681"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;260,833&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.31&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;260,833&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.22&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1209449450"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.84&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;108,334&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.31&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.84&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;108,334&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.84&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_478459098"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.85&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;40,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.29&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.85&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;40,000&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;6.85&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1651616215"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;7.34&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;180,918&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.73&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;7.34&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;180,918&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;7.34&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_15631382"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.07&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1.73&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8.07&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8.07&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2015684357"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;1.42&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.57&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,403,863&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.57&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,923&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_478771025"
      decimals="0"
      id="ixv-7862"
      unitRef="uref_1142227404">206945</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_926476485" id="ixv-7863">P0Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_478771025"
      decimals="2"
      id="ixv-7864"
      unitRef="uref_1838883110">1.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_478771025"
      decimals="0"
      id="ixv-7865"
      unitRef="uref_1142227404">206945</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_478771025"
      decimals="2"
      id="fc_324442161"
      unitRef="uref_1838883110">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_478771025"
      decimals="0"
      id="ixv-7867"
      unitRef="uref_1130380903">401473</ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_616493571"
      decimals="0"
      id="ixv-7868"
      unitRef="uref_1142227404">70000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_2003686783" id="ixv-7869">P0Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_616493571"
      decimals="2"
      id="ixv-7870"
      unitRef="uref_1838883110">2.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_616493571"
      decimals="0"
      id="ixv-7871"
      unitRef="uref_1142227404">70000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_616493571"
      decimals="2"
      id="fc_2095481122"
      unitRef="uref_1838883110">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_616493571"
      decimals="0"
      id="ixv-7873"
      unitRef="uref_1130380903">122500</ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_164717851"
      decimals="0"
      id="ixv-7874"
      unitRef="uref_1142227404">182500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_517838176" id="ixv-7875">P0Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_164717851"
      decimals="2"
      id="ixv-7876"
      unitRef="uref_1838883110">2.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_164717851"
      decimals="0"
      id="ixv-7877"
      unitRef="uref_1142227404">182500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_164717851"
      decimals="2"
      id="fc_600082269"
      unitRef="uref_1838883110">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_164717851"
      decimals="0"
      id="ixv-7879"
      unitRef="uref_1130380903">273750</ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1606065240"
      decimals="0"
      id="ixv-7880"
      unitRef="uref_1142227404">170000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_2016368059" id="ixv-7881">P0Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_1606065240"
      decimals="2"
      id="ixv-7882"
      unitRef="uref_1838883110">2.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_1606065240"
      decimals="0"
      id="ixv-7883"
      unitRef="uref_1142227404">170000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1606065240"
      decimals="2"
      id="fc_1061141367"
      unitRef="uref_1838883110">2.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_1606065240"
      decimals="0"
      id="ixv-7885"
      unitRef="uref_1130380903">214200</ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_266825755"
      decimals="0"
      id="ixv-7886"
      unitRef="uref_1142227404">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_258092401" id="ixv-7887">P0Y4M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_266825755"
      decimals="2"
      id="ixv-7888"
      unitRef="uref_1838883110">2.65</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_266825755"
      decimals="0"
      id="ixv-7889"
      unitRef="uref_1142227404">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_266825755"
      decimals="2"
      id="fc_1894454682"
      unitRef="uref_1838883110">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_266825755"
      decimals="0"
      id="ixv-7891"
      unitRef="uref_1130380903">24400</ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1609161670"
      decimals="0"
      id="ixv-7892"
      unitRef="uref_1142227404">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_610342924" id="ixv-7893">P0Y9M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_1609161670"
      decimals="2"
      id="ixv-7894"
      unitRef="uref_1838883110">2.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_1609161670"
      decimals="0"
      id="ixv-7895"
      unitRef="uref_1142227404">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1609161670"
      decimals="2"
      id="fc_26339350"
      unitRef="uref_1838883110">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_1609161670"
      decimals="0"
      id="ixv-7897"
      unitRef="uref_1130380903">33600</ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_2047779281"
      decimals="0"
      id="ixv-7898"
      unitRef="uref_1142227404">45667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_820516612" id="ixv-7899">P2Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_2047779281"
      decimals="2"
      id="ixv-7900"
      unitRef="uref_1838883110">5.47</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_2047779281"
      decimals="0"
      id="ixv-7901"
      unitRef="uref_1142227404">45667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_2047779281"
      decimals="2"
      id="fc_2047779281"
      unitRef="uref_1838883110">5.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1434214127"
      decimals="0"
      id="ixv-7903"
      unitRef="uref_1142227404">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_676550284" id="ixv-7904">P1Y2M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_1434214127"
      decimals="2"
      id="ixv-7905"
      unitRef="uref_1838883110">5.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_1434214127"
      decimals="0"
      id="ixv-7906"
      unitRef="uref_1142227404">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1434214127"
      decimals="2"
      id="fc_1434214127"
      unitRef="uref_1838883110">5.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1914682739"
      decimals="0"
      id="ixv-7908"
      unitRef="uref_1142227404">260833</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_1050754111" id="ixv-7909">P2Y3M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_1914682739"
      decimals="2"
      id="ixv-7910"
      unitRef="uref_1838883110">6.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_1914682739"
      decimals="0"
      id="ixv-7911"
      unitRef="uref_1142227404">260833</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1914682739"
      decimals="2"
      id="fc_1914682739"
      unitRef="uref_1838883110">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1680837298"
      decimals="0"
      id="ixv-7913"
      unitRef="uref_1142227404">108334</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_718138601" id="ixv-7914">P2Y3M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_1680837298"
      decimals="2"
      id="ixv-7915"
      unitRef="uref_1838883110">6.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_1680837298"
      decimals="0"
      id="ixv-7916"
      unitRef="uref_1142227404">108334</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1680837298"
      decimals="2"
      id="fc_1680837298"
      unitRef="uref_1838883110">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_487926479"
      decimals="0"
      id="ixv-7918"
      unitRef="uref_1142227404">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_398687509" id="ixv-7919">P2Y3M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_487926479"
      decimals="2"
      id="ixv-7920"
      unitRef="uref_1838883110">6.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_487926479"
      decimals="0"
      id="ixv-7921"
      unitRef="uref_1142227404">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_487926479"
      decimals="2"
      id="fc_487926479"
      unitRef="uref_1838883110">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1449916209"
      decimals="0"
      id="ixv-7923"
      unitRef="uref_1142227404">180918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_1775938043" id="ixv-7924">P1Y8M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_1449916209"
      decimals="2"
      id="ixv-7925"
      unitRef="uref_1838883110">7.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_1449916209"
      decimals="0"
      id="ixv-7926"
      unitRef="uref_1142227404">180918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1449916209"
      decimals="2"
      id="fc_1449916209"
      unitRef="uref_1838883110">7.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_1574703023"
      decimals="0"
      id="ixv-7928"
      unitRef="uref_1142227404">58666</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_385634131" id="ixv-7929">P1Y8M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_1574703023"
      decimals="2"
      id="ixv-7930"
      unitRef="uref_1838883110">8.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_1574703023"
      decimals="0"
      id="ixv-7931"
      unitRef="uref_1142227404">58666</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1574703023"
      decimals="2"
      id="fc_1574703023"
      unitRef="uref_1838883110">8.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="cref_545487639"
      decimals="0"
      id="ixv-7933"
      unitRef="uref_1142227404">1403863</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_1570954804" id="ixv-7934">P1Y5M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="cref_545487639"
      decimals="2"
      id="ixv-7935"
      unitRef="uref_1838883110">4.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="cref_545487639"
      decimals="0"
      id="ixv-7936"
      unitRef="uref_1142227404">1403863</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_545487639"
      decimals="2"
      id="fc_1838883110"
      unitRef="uref_1838883110">4.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue
      contextRef="cref_545487639"
      decimals="0"
      id="ixv-7938"
      unitRef="uref_1130380903">1069923</ntrb:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableIntrinsicValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_801113801" id="ixv-4638">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;9&lt;/td&gt; &lt;td&gt;SEGMENT REPORTING&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; We organize and manage our business by the following &lt;span style="-sec-ix-hidden:fc_11325532"&gt;two&lt;/span&gt; segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer- decision maker, who is our &lt;span style="-sec-ix-hidden:fc_216246343"&gt;chief executive officer&lt;/span&gt;, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Net Sales&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_4609531"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_621715936"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Gross Profit&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;196,801&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;251,981&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_571471521"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_73424698"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 0in; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;196,801&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,981&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Operating Expense&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Selling, general and administrative - Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;156,788&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;151,528&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Selling, general and administrative - 4P Therapeutics&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6,483&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;19,999&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Selling, general and administrative - Corporate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,049,734&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;810,525&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Goodwill and intangibles impairment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_425087357"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1682608058"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Research and development - 4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;238,229&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;683,426&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,451,234&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,665,478&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Depreciation and Amortization&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;24,910&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;42,813&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 9pt"&gt;Corporate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_280772982"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1511338803"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,267&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,267&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;34,177&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57,480&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Net Sales&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Outside the United States&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_496935024"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1427463371"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Property and equipment, not of accumulated depreciation&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;April 30,&lt;br/&gt;  2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;January 31,&lt;br/&gt;  2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;548,244&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;567,255&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Outside of the United States&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1336222078"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_570831292"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;548,244&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;567,255&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;Corporate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;3,818,051&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4,437,703&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,825,258&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,820,731&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,248,993&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,294,501&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,892,302&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,547,935&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="cref_801113801" id="ixv-4648">Separate financial information is available and regularly reviewed by our chief officer- decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. </us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="cref_801113801" id="ixv-7939">Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Net Sales&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_4609531"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_621715936"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left"&gt;Gross Profit&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;196,801&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;251,981&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_571471521"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_73424698"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 0in; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;196,801&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,981&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Operating Expense&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Selling, general and administrative - Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;156,788&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;151,528&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Selling, general and administrative - 4P Therapeutics&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6,483&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;19,999&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Selling, general and administrative - Corporate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,049,734&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;810,525&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Goodwill and intangibles impairment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_425087357"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1682608058"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Research and development - 4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;238,229&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;683,426&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,451,234&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,665,478&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left"&gt;Depreciation and Amortization&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;24,910&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;42,813&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-left: 9pt"&gt;Corporate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_280772982"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1511338803"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,267&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,267&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;34,177&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57,480&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="cref_1873059364"
      decimals="0"
      id="ixv-7940"
      unitRef="uref_1130380903">433399</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_1568411139"
      decimals="0"
      id="ixv-7941"
      unitRef="uref_1130380903">667432</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_2063022680"
      decimals="0"
      id="ixv-7942"
      unitRef="uref_1130380903">433399</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_1714920428"
      decimals="0"
      id="ixv-7943"
      unitRef="uref_1130380903">667432</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="cref_1873059364"
      decimals="0"
      id="ixv-7944"
      unitRef="uref_1130380903">196801</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="cref_1568411139"
      decimals="0"
      id="ixv-7945"
      unitRef="uref_1130380903">251981</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="cref_2063022680"
      decimals="0"
      id="ixv-7946"
      unitRef="uref_1130380903">196801</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="cref_1714920428"
      decimals="0"
      id="ixv-7947"
      unitRef="uref_1130380903">251981</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_442966646"
      decimals="0"
      id="ixv-7948"
      unitRef="uref_1130380903">156788</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_600097741"
      decimals="0"
      id="ixv-7949"
      unitRef="uref_1130380903">151528</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_770823313"
      decimals="0"
      id="ixv-7950"
      unitRef="uref_1130380903">6483</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_1751454475"
      decimals="0"
      id="ixv-7951"
      unitRef="uref_1130380903">19999</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_1029258840"
      decimals="0"
      id="ixv-7952"
      unitRef="uref_1130380903">1049734</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="cref_91145137"
      decimals="0"
      id="ixv-7953"
      unitRef="uref_1130380903">810525</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1796246010"
      decimals="0"
      id="ixv-7954"
      unitRef="uref_1130380903">238229</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_17202391"
      decimals="0"
      id="ixv-7955"
      unitRef="uref_1130380903">683426</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="cref_2063022680"
      decimals="0"
      id="ixv-7956"
      unitRef="uref_1130380903">1451234</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_1714920428"
      decimals="0"
      id="ixv-7957"
      unitRef="uref_1130380903">1665478</us-gaap:OperatingExpenses>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1873059364"
      decimals="0"
      id="ixv-7958"
      unitRef="uref_1130380903">24910</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1568411139"
      decimals="0"
      id="ixv-7959"
      unitRef="uref_1130380903">42813</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_802128550"
      decimals="0"
      id="ixv-7960"
      unitRef="uref_1130380903">9267</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1310356150"
      decimals="0"
      id="ixv-7961"
      unitRef="uref_1130380903">9267</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_2063022680"
      decimals="0"
      id="ixv-7962"
      unitRef="uref_1130380903">34177</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1714920428"
      decimals="0"
      id="ixv-7963"
      unitRef="uref_1130380903">57480</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="cref_801113801" id="ixv-4906">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center"&gt;Three Months Ending&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;April 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;Net Sales&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Outside the United States&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_496935024"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1427463371"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;433,399&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;667,432&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Property and equipment, not of accumulated depreciation&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;April 30,&lt;br/&gt;  2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;January 31,&lt;br/&gt;  2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;548,244&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;567,255&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Outside of the United States&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1336222078"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_570831292"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;548,244&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;567,255&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td&gt;Assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-left: 9pt"&gt;Corporate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;3,818,051&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;4,437,703&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="text-align: left; padding-left: 9pt"&gt;Pocono Pharmaceuticals&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,825,258&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1,820,731&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;4P Therapeutics&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,248,993&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,294,501&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,892,302&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,547,935&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="cref_1247594112"
      decimals="0"
      id="ixv-7964"
      unitRef="uref_1130380903">433399</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_775598171"
      decimals="0"
      id="ixv-7965"
      unitRef="uref_1130380903">667432</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_2063022680"
      decimals="0"
      id="ixv-7966"
      unitRef="uref_1130380903">433399</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_1714920428"
      decimals="0"
      id="ixv-7967"
      unitRef="uref_1130380903">667432</us-gaap:Revenues>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_445070040"
      decimals="0"
      id="ixv-7968"
      unitRef="uref_1130380903">548244</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1610623169"
      decimals="0"
      id="ixv-7969"
      unitRef="uref_1130380903">567255</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1272226741"
      decimals="0"
      id="ixv-7970"
      unitRef="uref_1130380903">548244</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1426843771"
      decimals="0"
      id="ixv-7971"
      unitRef="uref_1130380903">567255</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="cref_1933620450"
      decimals="0"
      id="ixv-7972"
      unitRef="uref_1130380903">3818051</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_403041879"
      decimals="0"
      id="ixv-7973"
      unitRef="uref_1130380903">4437703</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1031402892"
      decimals="0"
      id="ixv-7974"
      unitRef="uref_1130380903">1825258</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1244462413"
      decimals="0"
      id="ixv-7975"
      unitRef="uref_1130380903">1820731</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1013089313"
      decimals="0"
      id="ixv-7976"
      unitRef="uref_1130380903">1248993</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1593737962"
      decimals="0"
      id="ixv-7977"
      unitRef="uref_1130380903">1294501</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1272226741"
      decimals="0"
      id="ixv-7978"
      unitRef="uref_1130380903">6892302</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1426843771"
      decimals="0"
      id="ixv-7979"
      unitRef="uref_1130380903">7547935</us-gaap:Assets>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_801113801" id="ixv-5077">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;10.&lt;/td&gt; &lt;td&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#x2019; notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000. These agreements, and the employment of Mr. Goodman, automatically renew for one-year terms following expiration of the initial three-year terms and each successive one-year term. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days&#x2019; notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.4pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;i&gt;Kindeva Drug Delivery Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On January 4, 2024, the Company signed a commercial development and clinical supply agreement for their lead product, Aversa Fentanyl, with Kindeva Drug Delivery, L.P. (&#x201c;Kindeva&#x201d;). Under this agreement, Kindeva will perform commercial manufacturing process development, manufacturing of clinical supplies for the human abuse liability clinical study, and development of chemistry, manufacturing and controls (CMC) information required by the FDA in support of a New Drug Application (&#x201c;NDA&#x201d;). As of April 30, 2026, the Company has incurred expenses of $5.2 million under this agreement. On February 4, 2025, the agreement was amended to reduce the hourly rate for the labor on the project in exchange for a milestone payment payable upon FDA approval. Under the amended Kindeva agreement, the remaining budget as of April 30, 2026, through NDA submission for the current workplan is $3.4 million. The amended agreement also includes a milestone payment of $3.0 million to be paid to Kindeva when the Company receives FDA approval. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Lease Agreement&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt; On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expired on January 31, 2025. The lease has been extended for an additional three years at the same monthly rental. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Sorrento Therapeutics, Inc. Agreement&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt; On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of April 30, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Legal Proceedings&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt; The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (&#x201c;Gunnar&#x201d;) and Lucosky Brookman LLP (&#x201c;LB&#x201d;) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company&#x2019;s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt; In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar &amp;amp; Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt; Currently, there are no pending hearings or motions, and the case is in the discovery stage. In early 2024, the plaintiffs proposed a settlement offer of $100,000. The Company has not responded to that proposed settlement offer. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Termination Agreement&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"&gt; On February 13, 2026, the Company&#x2019;s Board of Directors approved the termination immediately of the Company&#x2019;s agreement for the sale of its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc., due to the purchaser&#x2019;s failure to pay applicable late fees under the purchase agreement for their not closing on the December 31, 2025 closing date under the purchase agreement. The Company received $30,000 in late fees but have not received any further payments since January 21, 2026. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ntrb:EmploymentAgreementExpirationDate contextRef="cref_801113801" id="ixv-7980">2025-01-31</ntrb:EmploymentAgreementExpirationDate>
    <ntrb:AnnualSalaryReceivedPerAnnum
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7981"
      unitRef="uref_1130380903">250000</ntrb:AnnualSalaryReceivedPerAnnum>
    <ntrb:PercentageOfNetIncome
      contextRef="cref_801113801"
      decimals="3"
      id="ixv-7982"
      unitRef="uref_490212018">0.035</ntrb:PercentageOfNetIncome>
    <ntrb:AnnualSalaryReducedPerAnnum
      contextRef="cref_617777440"
      decimals="0"
      id="fc_617777440"
      unitRef="uref_1130380903">150000</ntrb:AnnualSalaryReducedPerAnnum>
    <ntrb:AnnualSalaryReceivedPerAnnum
      contextRef="cref_571041992"
      decimals="0"
      id="ixv-7984"
      unitRef="uref_1130380903">210000</ntrb:AnnualSalaryReceivedPerAnnum>
    <ntrb:AnnualSalaryReducedPerAnnum
      contextRef="cref_1912646503"
      decimals="0"
      id="fc_1912646503"
      unitRef="uref_1130380903">110000</ntrb:AnnualSalaryReducedPerAnnum>
    <us-gaap:OtherExpenses
      contextRef="cref_1355163824"
      decimals="-5"
      id="ixv-7986"
      unitRef="uref_1130380903">5200000</us-gaap:OtherExpenses>
    <ntrb:EstimatedCost
      contextRef="cref_801113801"
      decimals="-5"
      id="ixv-7987"
      unitRef="uref_1130380903">3400000</ntrb:EstimatedCost>
    <ntrb:MilestonePayments
      contextRef="cref_801113801"
      decimals="-5"
      id="ixv-7988"
      unitRef="uref_1130380903">3000000</ntrb:MilestonePayments>
    <us-gaap:AreaOfLand
      contextRef="cref_1964202127"
      decimals="0"
      id="ixv-7989"
      unitRef="uref_1964202127">12000</us-gaap:AreaOfLand>
    <us-gaap:PaymentsForRent
      contextRef="cref_606350720"
      decimals="0"
      id="ixv-7990"
      unitRef="uref_1130380903">3000</us-gaap:PaymentsForRent>
    <us-gaap:LeaseExpirationDate1 contextRef="cref_606350720" id="ixv-7991">2025-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="cref_1955509422"
      decimals="0"
      id="ixv-7992"
      unitRef="uref_1130380903">106528</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:CashAndDueFromBanks
      contextRef="cref_546947719"
      decimals="0"
      id="ixv-7993"
      unitRef="uref_1130380903">118675</us-gaap:CashAndDueFromBanks>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="cref_390752152"
      decimals="0"
      id="ixv-7994"
      unitRef="uref_1130380903">118675</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:LegalFees
      contextRef="cref_801113801"
      decimals="0"
      id="ixv-7995"
      unitRef="uref_1130380903">500000</us-gaap:LegalFees>
    <us-gaap:Cash
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7996"
      unitRef="uref_1130380903">1000000</us-gaap:Cash>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="cref_1599877957"
      decimals="0"
      id="ixv-7997"
      unitRef="uref_1130380903">100000</us-gaap:SettlementLiabilitiesCurrent>
    <ntrb:TerminationLateFees
      contextRef="cref_1660901923"
      decimals="0"
      id="ixv-7998"
      unitRef="uref_1130380903">30000</ntrb:TerminationLateFees>
    <us-gaap:SubsequentEventsTextBlock contextRef="cref_801113801" id="ixv-5135">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 0"&gt;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;11.&lt;/td&gt; &lt;td&gt;SUBSEQUENT EVENTS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0.5in"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="text-align: justify"&gt;On June 1, 2026, the Company and TII Jet Services amended their credit line facility agreement in light of the expiration of the facility in the near future. The parties extended the $5 million credit line to June 30,2029.&#160;At this time, the Company has no outstanding drawn-down amounts under this facility.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCredit
      contextRef="cref_1130380903"
      decimals="-6"
      id="ixv-7999"
      unitRef="uref_1130380903">5000000</us-gaap:LineOfCredit>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="cref_801113801" id="ixv-8000">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="cref_801113801" id="ixv-8001">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="cref_801113801" id="ixv-8002">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="cref_801113801" id="ixv-8003">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
